Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...
Nature10y
Seeing mTOR in a new light
an endogenous negative regulator of mTOR activity), in which mTOR is hyperactive: Tsc2 −/− cells produced less IL-12 and more IL-10 following LPS stimulation compared with wild-type cells.